Genmab A/S (GNMSF)
USD 203.33
(0.0%)
USD 203.33
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 680 Million DKK | 30.02% |
| 2022 | 523 Million DKK | 44.08% |
| 2021 | 363 Million DKK | 31.05% |
| 2020 | 277 Million DKK | 78.71% |
| 2019 | 155 Million DKK | 0.0% |
| 2018 | - DKK | 0.0% |
| 2017 | - DKK | 0.0% |
| 2016 | - DKK | 0.0% |
| 2015 | - DKK | -100.0% |
| 2014 | 118 Thousand DKK | -66.85% |
| 2013 | 356 Thousand DKK | -81.18% |
| 2012 | 1.89 Million DKK | -68.76% |
| 2011 | 6.05 Million DKK | -48.88% |
| 2010 | 11.84 Million DKK | -33.96% |
| 2009 | 17.93 Million DKK | 100.11% |
| 2008 | 8.96 Million DKK | 9.56% |
| 2007 | 8.18 Million DKK | -27.28% |
| 2006 | 11.25 Million DKK | -22.33% |
| 2005 | 14.48 Million DKK | -30.89% |
| 2004 | 20.96 Million DKK | 12.88% |
| 2003 | 18.56 Million DKK | 74.76% |
| 2002 | 10.62 Million DKK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 918 Million DKK | 0.0% |
| 2024 Q2 | 925 Million DKK | 0.0% |
| 2023 Q2 | 721 Million DKK | -2.57% |
| 2023 Q1 | 740 Million DKK | 41.49% |
| 2023 Q4 | 680 Million DKK | -4.23% |
| 2023 FY | 680 Million DKK | 30.02% |
| 2023 Q3 | 710 Million DKK | -1.53% |
| 2022 Q2 | 554 Million DKK | 55.62% |
| 2022 Q3 | 550 Million DKK | -0.72% |
| 2022 Q4 | 523 Million DKK | -4.91% |
| 2022 Q1 | 356 Million DKK | -1.93% |
| 2022 FY | 523 Million DKK | 44.08% |
| 2021 Q1 | 326 Million DKK | 17.69% |
| 2021 Q2 | 384 Million DKK | 17.79% |
| 2021 Q3 | 374 Million DKK | -2.6% |
| 2021 Q4 | 363 Million DKK | -2.94% |
| 2021 FY | 363 Million DKK | 31.05% |
| 2020 FY | 277 Million DKK | 78.71% |
| 2020 Q1 | 148 Million DKK | -4.52% |
| 2020 Q2 | 313 Million DKK | 111.49% |
| 2020 Q3 | 295 Million DKK | -5.75% |
| 2020 Q4 | 277 Million DKK | -6.1% |
| 2019 Q3 | 157.61 Million DKK | -3.19% |
| 2019 Q4 | 155 Million DKK | -1.66% |
| 2019 FY | 155 Million DKK | 0.0% |
| 2019 Q2 | 162.81 Million DKK | -3.25% |
| 2019 Q1 | 168.27 Million DKK | 0.0% |
| 2018 Q2 | - DKK | 0.0% |
| 2018 Q1 | - DKK | 0.0% |
| 2018 FY | - DKK | 0.0% |
| 2018 Q4 | - DKK | 0.0% |
| 2018 Q3 | - DKK | 0.0% |
| 2017 FY | - DKK | 0.0% |
| 2017 Q3 | - DKK | 0.0% |
| 2017 Q4 | - DKK | 0.0% |
| 2017 Q2 | - DKK | 0.0% |
| 2017 Q1 | - DKK | 0.0% |
| 2016 Q4 | - DKK | 0.0% |
| 2016 Q3 | - DKK | 0.0% |
| 2016 Q2 | - DKK | 0.0% |
| 2016 Q1 | - DKK | 0.0% |
| 2016 FY | - DKK | 0.0% |
| 2015 Q2 | - DKK | -100.0% |
| 2015 Q1 | 59 Thousand DKK | -50.0% |
| 2015 FY | - DKK | -100.0% |
| 2015 Q4 | - DKK | 0.0% |
| 2015 Q3 | - DKK | 0.0% |
| 2014 Q1 | 297 Thousand DKK | -16.57% |
| 2014 Q4 | 118 Thousand DKK | -33.71% |
| 2014 Q2 | 237 Thousand DKK | -20.2% |
| 2014 Q3 | 178 Thousand DKK | -24.89% |
| 2014 FY | 118 Thousand DKK | -66.85% |
| 2013 Q2 | 475 Thousand DKK | -48.65% |
| 2013 FY | 356 Thousand DKK | -81.18% |
| 2013 Q4 | 356 Thousand DKK | -14.22% |
| 2013 Q3 | 415 Thousand DKK | -12.63% |
| 2013 Q1 | 925 Thousand DKK | -51.11% |
| 2012 FY | 1.89 Million DKK | -68.76% |
| 2012 Q1 | 4.73 Million DKK | -21.86% |
| 2012 Q2 | 3.79 Million DKK | -19.8% |
| 2012 Q3 | 2.84 Million DKK | -24.95% |
| 2012 Q4 | 1.89 Million DKK | -33.57% |
| 2011 Q4 | 6.05 Million DKK | 1.02% |
| 2011 Q2 | 8.7 Million DKK | -15.54% |
| 2011 FY | 6.05 Million DKK | -48.88% |
| 2011 Q1 | 10.3 Million DKK | -12.99% |
| 2011 Q3 | 5.99 Million DKK | -31.13% |
| 2010 Q3 | 13.38 Million DKK | -10.2% |
| 2010 Q1 | 16.4 Million DKK | -8.55% |
| 2010 FY | 11.84 Million DKK | -33.96% |
| 2010 Q2 | 14.9 Million DKK | -9.16% |
| 2010 Q4 | 11.84 Million DKK | -11.48% |
| 2009 FY | 17.93 Million DKK | 100.11% |
| 2009 Q4 | 17.93 Million DKK | 0.0% |
| 2008 FY | 8.96 Million DKK | 9.56% |
| 2007 FY | 8.18 Million DKK | -27.28% |
| 2006 FY | 11.25 Million DKK | -22.33% |
| 2005 FY | 14.48 Million DKK | -30.89% |
| 2004 FY | 20.96 Million DKK | 12.88% |
| 2003 FY | 18.56 Million DKK | 74.76% |
| 2002 FY | 10.62 Million DKK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | -3152.188% |
| Evofem Biosciences, Inc. | 8000.00 USD | -8499900.0% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -38635.866% |
| Mesoblast Limited | 100.29 Million USD | -578.0% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -1159478.459% |
| Genus plc | 228.2 Million USD | -197.984% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Marizyme, Inc. | 667.12 Thousand USD | -101829.312% |
| ContraFect Corporation | 2.21 Million USD | -30669.231% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -48369.85% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -12431.144% |
| MultiCell Technologies, Inc. | 36.43 USD | -1866593366.923% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | -1122.758% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -30448.068% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -55258.319% |
| Biomind Labs Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | -309.38% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -35718.355% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -397026.672% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -12336619.884% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| IMV Inc. | 27.39 Million USD | -2381.881% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -211080.124% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 93.95% |
| Halberd Corporation | 150 Thousand USD | -453233.333% |
| Enzolytics Inc. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 300 Thousand USD | -226566.667% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -414016.501% |
| argenx SE | 15.35 Million USD | -4328.813% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | -3247.775% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -15260223.16% |
| Genscript Biotech Corporation | 287.12 Million USD | -136.827% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -538292.108% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -296466.372% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -122513.102% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -2687753.275% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -8128.461% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -255890.363% |
| ONE Bio Corp. | 592.19 Thousand USD | -114726.46% |
| Reve Technologies, Inc. | 1064.00 USD | -63909674.436% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -454402.921% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -454402.921% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -295949.911% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -482169.504% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 80 Thousand USD | -849900.0% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -8595.697% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -184157.375% |
| International Stem Cell Corporation | 445 Thousand USD | -152708.989% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -8243.558% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -148696.499% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -58470.198% |
| PureTech Health plc | 18.25 Million USD | -3626.027% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -453233.333% |
| IXICO plc | 275 Thousand USD | -247172.727% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -5643.728% |
| Gelesis Holdings, Inc. | 26.3 Million USD | -2484.667% |
| CSL Limited | 11.23 Billion USD | 93.95% |
| Cellectis S.A. | 36.21 Million USD | -1777.875% |